Teclistamab for Multiple Myeloma Therapy: A Literature Review and the First Clinical Use in Russia

The modern paradigm for the treatment of hematologic tumors can hardly be imagined without immunotherapy including the most rapidly developing group of drugs referred to as bispecific antibodies. Teclistamab is a humanized bispecific antibody created for targeted impact on the B-cell maturation antigen (BCMA) expressed in multiple myeloma and CD3 receptor located on the surface of T-lymphocytes. BCMA is a transmembrane protein, a member of the tumor necrosis factor receptor superfamily. It is essential for the survival of plasma cells and is characterized by minimal expression on non-hematopoietic cells. Currently, there are three main BCMA-targeting treatment approaches having unique advantages and certain restrictions. Antibody-drug conjugates (ADC) show moderate efficacy as monotherapy and high efficacy in combination with other drugs in relapsed/refractory multiple myeloma (r/r MM), but their use is limited by ocular toxicity. The therapy with chimeric antigen receptors (CAR) of T-cells is considered the most promising approach, which, however, is not free of substantial logistic and economic restrictions. Bispecific antibodies, on the other hand, show high efficacy and acceptable toxicity profile compared to ADC, although their long-term administration poses a cumulative risk for infectious complications. This paper provides a literature review and reports the first experience in administration of teclistamab, a bispecific antibody drug, as a monoregimen in a r/r MM female patient with triple refractoriness to the previous treatment.

• Anastasiya Aleksandrovna Semenova NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 https://orcid.org/0000-0003-4951-3053 (unauthenticated)
• A.S. Luchinin NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 https://orcid.org/0009-0006-0020-3168 (unauthenticated)
• A.S. Subbotin NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 https://orcid.org/0000-0002-4648-2362 (unauthenticated)
• G.S. Tumyan NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 https://orcid.org/0000-0002-5771-4413 (unauthenticated)
• A.V. Arakelyan NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 ; IM Sechenov First Moscow State Medical University, 2 korp. 4 Bolshaya Pirogovskaya ul., Moscow, Russian Federation, 119435 https://orcid.org/0000-0003-4911-0959 (unauthenticated)
• A.I. Cherencova NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522 https://orcid.org/0009-0002-3791-0107 (unauthenticated)
• S.S. Kamyshanov NI Pirogov Russian National Research Medical University, 1 Ostrovityanova ul., Moscow, Russian Federation, 117513 https://orcid.org/0009-0007-1455-5137 (unauthenticated)

1. Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4(18):4538–49. doi: 10.1182/bloodadvances.2020002393. DOI: https://doi.org/10.1182/bloodadvances.2020002393
2. Guo Y, Quijano Cardé NA, Kang L, et al. Teclistamab: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1):e13717. doi: 10.1111/cts.13717. DOI: https://doi.org/10.1111/cts.13717
3. Kawasaki Y, Winger S, Esteghamat N, et al. Practical insights into bispecific antibody therapy in multiple myeloma. Expert Rev Anticancer Ther. 2024;24(12):1209–19. doi: 10.1080/14737140.2024.2445145. DOI: https://doi.org/10.1080/14737140.2024.2445145
4. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38. doi: 10.1016/j.bbmt.2018.12.758. DOI: https://doi.org/10.1016/j.bbmt.2018.12.758
5. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505. doi: 10.1056/NEJMoa2203478. DOI: https://doi.org/10.1056/NEJMoa2203478
6. Rees MJ, Kumar S. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them. Leuk Lymphoma. 2024;65(3):287–300. doi: 10.1080/10428194.2023.2284088. DOI: https://doi.org/10.1080/10428194.2023.2284088
7. Rodriguez-Otero P, Dholaria B, Askari E, et al. B04: Combination of subcutaneous teclistamab with daratumumab in patients with relapsed/refractory multiple myeloma (RRMM): results from a phase 1b multicohort study. HemaSphere. 2022;6(Suppl):7. doi: 10.1097/01.HS9.0000829556.56345.01. DOI: https://doi.org/10.1097/01.HS9.0000829556.56345.01
8. Cohen YC, Magen H, Gatt M, et al. Talquetamab plus Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392(2):138–49. doi: 10.1056/NEJMoa2406536. DOI: https://doi.org/10.1056/NEJMoa2406536
9. Searle E, Quach H, Wong SW, et al. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase 1b, multicohort study. Blood. 2022;140(Suppl 1):394–6. doi: 10.1182/blood-2022-159711. DOI: https://doi.org/10.1182/blood-2022-159711
10. Mohan M, Monge J, Shah N, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14(1):35. doi: 10.1038/s41408-024-01003-z. DOI: https://doi.org/10.1038/s41408-024-01003-z
11. Riedhammer C, Bassermann F, Besemer B, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38(2):365–71. doi: 10.1038/s41375-024-02154-5. DOI: https://doi.org/10.1038/s41375-024-02154-5
12. Varma G, Fogel L, Gordon B, et al. Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis. Leuk Lymphoma. 2025;66(5):942–51. doi: 10.1080/10428194.2024.2446617. DOI: https://doi.org/10.1080/10428194.2024.2446617